STROBE Statement—Checklist of items that should be included in reports of ***cohort studies***

|  |  |  |  |
| --- | --- | --- | --- |
|  | Item No | Recommendation | Section and Paragraph No |
| **Title and abstract** | 1 | (*a*) Indicate the study’s design with a commonly used term in the title or the abstract | (a) Title: 1 |
| (*b*) Provide in the abstract an informative and balanced summary of what was done and what was found | (b) Abstract: paragraphs 1-3 |
| Introduction |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Introduction: paragraphs 1-5 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | Introduction: paragraph 6 |
| Methods |
| Study design | 4 | Present key elements of study design early in the paper | Methods: paragraph 1 (Study Design) |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Methods: paragraph 1 (Study Design) |
| Participants | 6 | (*a*) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | (a) Methods: paragraph 2 (Eligibility Criteria) |
| (*b*)For matched studies, give matching criteria and number of exposed and unexposed | (b) N/A |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Methods: paragraph 3 (Pathologic Response Assessment) |
| Data sources/ measurement | 8\* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Methods: paragraphs 3-14 (Pathologic response assessment – Identifying Actionable Mutations from utDNA Analysis) |
| Bias | 9 | Describe any efforts to address potential sources of bias | Methods: paragraphs 1 (Study Design) and 15 (Power and Statistical Analyses)  |
| Study size | 10 | Explain how the study size was arrived at | Methods: paragraph 15 (Power and Statistical Analyses) |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Methods: paragraphs 16-19 (Power and Statistical Analyses) |
| Statistical methods | 12 | (*a*) Describe all statistical methods, including those used to control for confounding | (a) Methods: paragraphs 16-19 (Power and Statistical Analyses) |
| (*b*) Describe any methods used to examine subgroups and interactions | (b) Methods: paragraphs 16-19 (Power and Statistical Analyses) |
| (*c*) Explain how missing data were addressed | (c) Methods: paragraph 1 (Study Design) |
| (*d*) If applicable, explain how loss to follow-up was addressed | (d) N/A |
| (*e*) Describe any sensitivity analyses | (e) N/A |
| Results |  |
| Participants | 13\* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | (a) Methods: paragraph 1 (Study Design) |
| (b) Give reasons for non-participation at each stage | (b) Methods: paragraphs 1-2 (Study Design - Eligibility Criteria) |
| (c) Consider use of a flow diagram | (c) Methods: Figure 1 |
| Descriptive data | 14\* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | (a) Methods: Table 1,Results: paragraph 1 (cohort characteristics) |
| (b) Indicate number of participants with missing data for each variable of interest | (b) Methods: Figure 1 |
| (c) Summarise follow-up time (eg, average and total amount) | (c) Methods: Table 1 |
| Outcome data | 15\* | Report numbers of outcome events or summary measures over time | Methods: paragraph 4 (Non-Silent Mutations Classify Pathologic Response) |
| Main results | 16 | (*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | (a) Results: paragraphs 8-11 (No pCR is Associated with Higher utDNA Levels than pCR, paragraphs 12-13 (utDNA MRD as a Prognostic Biomarker) |
| (*b*) Report category boundaries when continuous variables were categorized | (b) N/A |
| (*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | (c) N/A |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | Results: paragraphs 14-19 (Serial Tracking of utDNA variants during neoadjuvant chemotherapy), paragraphs 20-24 (utDNA MRD Oncogenomics for Treatment Personalization) |
| Discussion |
| Key results | 18 | Summarise key results with reference to study objectives | Discussion: paragraphs 1-5 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Discussion: paragraph 6 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Discussion: paragraphs 1-9 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Methods: paragraph 2 (Eligibility Criteria), Results: paragraph 10 (No pCR is Associated with Higher utDNA Levels than pCR), Discussion: paragraphs 6-8 |
| Other information |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Acknowledgements |

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.